Pharnext (PNEXF) Stock Price, News & Analysis

Company Overview

Pharnext SA (OTCMKTS:PNEXF) is a clinical‐stage biopharmaceutical company based in Paris, France, dedicated to developing innovative treatments for rare neurological and neuromuscular disorders. The company’s proprietary discovery platform, Pleotherapy, employs bioinformatics and machine learning to identify synergistic combinations of existing compounds, with the goal of accelerating drug development and improving patient outcomes.

Pharnext’s lead candidate, PXT3003, is undergoing advanced clinical evaluation for Charcot‐Marie‐Tooth disease type 1A (CMT1A), a hereditary peripheral neuropathy. Additional programs include PXT864 for amyotrophic lateral sclerosis (ALS) and PXT258 for Alzheimer’s disease, each designed to leverage low‐dose combinations of approved drugs to enhance efficacy while minimizing safety risks. By focusing on repurposed agents, Pharnext aims to reduce the time and cost typically associated with novel drug discovery.

Founded in 2007 as a spin‐off from French academic research, Pharnext has established collaborations with universities, non‐profit organizations and contract research organizations across Europe and North America. The company has conducted multi‐center clinical trials in several countries and is preparing regulatory submissions to expand access to its pipeline globally. Pharnext’s management team draws on extensive experience in drug development, translational research and regulatory affairs to advance its programs toward commercialization.

Key Stats

• Today's Range: $400.00 to $400.00
• 50-Day Range: $400.00 to $400.00
• 52-Week Range: $0.0001 to $0.0010
• Volume: 16,660 shs
• Average Volume: 433 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PNEXF
• CIK: N/A
• Web: www.pharnext.com
• Phone: (314) 109-2230
• Fax: N/A
• Employees: 23
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A